Corresponding Authors: Zhong Liu, MD, PhD, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 26 Huacai Rd, Longtan Industry Zone, Chenghua District, 610052, Chengdu, Sichuan, China (email@example.com); Yanyun Wu, MD, PhD, University of Miami, Department of Pathology, 1611 NW 12th Ave, Miami, FL 33136 (firstname.lastname@example.org).
Accepted for Publication: May 23, 2020.
Published Online: June 3, 2020. doi:10.1001/jama.2020.10044
Correction: This article was corrected on August 4. 2020, to fix some odds ratios in the Abstract, Results, and Table 3; some baseline laboratory data in Table 1; corresponding data in Supplement 3; and eFigure 1.
Author Contributions: Dr Z. Liu had full access to all of the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs L. Li, W. Zhang, and Y. Hu are co–first authors. Drs L. Li, W. Zhang, Y. Hu, X. Tong, S. Zheng, J. Yang, Y. Kong, L. Ren, Q. Wei, H. Mei, C. Hu, C. Tao, R. Yang, J. Wang, and Y. Yu contributed equally to the study.
Concept and design: L. Li, W. Zhang, X. Tong, J. Yang, N. Xiong, L. Zhang, J.W. Wang, Y. Wu, Z. Liu.
Acquisition, analysis, or interpretation of data: W. Zhang, S. Zheng, Y. Kong, L. Ren, Q. Wei, H. Mei, C. Hu, C. Tao, R. Yang, Jue Wang, Y. Yu, Y. Guo, X. Wu, Z. Xu, N. Xiong, L. Chen, Juan Wang, N. Man, Y. Liu, H. Xu, E. Deng, X. Zhang, C. Li, C. Wang, S. Su, Y. Hu, Y. Wu, Z. Liu.
Drafting of the manuscript: L. Li, W. Zhang, Y. Kong, L. Ren, H. Xu, E. Deng, C. Wang, Y. Wu, Z. Liu.
Critical revision of the manuscript for important intellectual content: W. Zhang, X. Tong, S. Zheng, J. Yang, Q. Wei, H. Mei, C. Hu, C. Tao, R. Yang, Jue Wang, Y. Yu, Y. Guo, X. Wu, Z. Xu, L. Zeng, N. Xiong, L. Chen, Juan Wang, N. Man, Y. Liu, X. Zhang, C. Li, S. Su, L. Zhang, Juan Wang, Y. Hu, Y. Wu, Z. Liu.
Statistical analysis: J. Yang, Y. Kong, Y. Yu.
Obtained funding: L. Li, Z. Liu.
Administrative, technical, or material support: L. Li, W. Zhang, X. Tong, L. Ren, H. Mei, Jue Wang, Y. Guo, N. Xiong, Y. Liu, H. Xu, E. Deng, C. Wang, S. Su, J.W. Wang, Z. Liu.
Supervision: W. Zhang, J. Yang, H. Mei, Y. Hu.
Conflict of Interest Disclosures: Dr Liu reports holding a pending patent on COVID-19 testing. Dr Wu reports consulting for Verax Medical and Grifols, receiving royalties from UptoDate and AABB, and being a volunteer visiting professor and receiving travel support for giving medical education from the Chinese Institute of Blood Transfusion. No other disclosures were reported.
Funding/Support: This work was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) grants 2020-I2M-CoV19-006, 2016-I2M-3-024 (Dr Z. Liu), and 2017-I2M-1-009 (Dr L. Li) and the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences grant 2018PT32016 (Dr Z. Liu).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We would like to thank the following individuals for their guidance, expertise, and assistance with the study design: Peter W. Marks, MD, PhD, Center for Biologics Evaluation and Research, FDA; Anne Eder, MD, PhD, Center for Biologics Evaluation and Research, FDA; Nicole Verdun, MD, Center for Biologics Evaluation and Research, FDA; Tim Uyeki, MD, MPH, MPP, National Center for Immunization and Respiratory Diseases, CDC; Scott Koepsell, MD, PhD, University of Nebraska Medical Center; Annie Winkler, MD, Instrumentation Laboratory; Xuan Qin, PhD, Seattle Children’s Hospital and University of Washington. None received compensation related to this study.
Z , McGoogan
JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA
. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648
KM , Chiueh
TS , Siu
et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother
. 2005;56(5):919-922. doi:10.1093/jac/dki346
CS , Hewlett
AL , Koepsell
et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis
. 2015;61(4):496-502. doi:10.1093/cid/civ334
Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus. In: Network WBR, ed. 2017. Accessed April 18, 2020. https://www.who.int/bloodproducts/brn/en/
DG . Evaluating the proportional hazards assumption. In: Survival Analysis. Statistics in the Health Sciences. Springer; 1996:183-184.